MovDisordV3, PascalFrancis, Corpus, bibRecord, 000F97

Cardiac and Noncardiac Fibrotic Reactions Caused by Ergot-and Nonergot-Derived Dopamine Agonists

Identifieur interne : 000F97 ( PascalFrancis/Corpus ); précédent : 000F96; suivant : 000F98

Cardiac and Noncardiac Fibrotic Reactions Caused by Ergot-and Nonergot-Derived Dopamine Agonists

Auteurs : Frank Andersohn ; Edeltraut Garbe

Source :

Movement disorders [ 0885-3185 ] ; 2009.

RBID : Pascal:09-0094116

Descripteurs français

Pascal (Inist)
- Pathologie du système nerveux, Stimulant dopaminergique, Fibrose.

English descriptors

KwdEn :
- Dopamine agonist, Fibrosis, Nervous system diseases.

Abstract

There is growing evidence that the ergot-derived dopamine agonists cabergoline and pergolide can cause fibrotic cardiac valvulopathy. Data on other fibrotic reactions and nonergot-derived dopamine agonists are sparse. Aim of this study was to investigate whether there are signals that dopamine agonists are related to cardiac and other fibrotic reactions. We identified all reports of fibrotic reactions at the heart, lung, and retroperitoneal space associated with dopamine agonists within the US Adverse Event Reporting System database. Disproportionality analyses were used to calculate adjusted reporting odds ratios (RORs). For ergot-derived dopamine agonists (bromocriptine, cabergoline, pergolide), the RORs of all reactions under study were increased, whereas no such increases were observed for nonergot-derived drugs (apomorphine, pramipexole, ropinirole, rotigotine). Fibrotic reactions due to ergot-derived dopamine agonists may not be limited to heart valves. For nonergot-derived dopamine agonists, no drug safety signals were evident.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 24`
A06				`@2 1`
A08	`01`	`1`	`ENG`	`@1 Cardiac and Noncardiac Fibrotic Reactions Caused by Ergot-and Nonergot-Derived Dopamine Agonists`
A11	`01`	`1`		`@1 ANDERSOHN (Frank)`
A11	`02`	`1`		`@1 GARBE (Edeltraut)`
A14	`01`			`@1 Bremen Institute for Prevention Research and Social Medicine, University of Bremen @3 DEU @Z 1 aut. @Z 2 aut.`
A14	`02`			`@1 Institute of Clinical Pharmacology and Toxicology, Charité Universitaetsmedizin Berlin @3 DEU @Z 2 aut.`
A20				`@1 129-133`
A21				`@1 2009`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000186473060210`
A44				`@0 0000 @1 © 2009 INIST-CNRS. All rights reserved.`
A45				`@0 19 ref.`
A47	`01`	`1`		`@0 09-0094116`
A60				`@1 P @3 CC`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 There is growing evidence that the ergot-derived dopamine agonists cabergoline and pergolide can cause fibrotic cardiac valvulopathy. Data on other fibrotic reactions and nonergot-derived dopamine agonists are sparse. Aim of this study was to investigate whether there are signals that dopamine agonists are related to cardiac and other fibrotic reactions. We identified all reports of fibrotic reactions at the heart, lung, and retroperitoneal space associated with dopamine agonists within the US Adverse Event Reporting System database. Disproportionality analyses were used to calculate adjusted reporting odds ratios (RORs). For ergot-derived dopamine agonists (bromocriptine, cabergoline, pergolide), the RORs of all reactions under study were increased, whereas no such increases were observed for nonergot-derived drugs (apomorphine, pramipexole, ropinirole, rotigotine). Fibrotic reactions due to ergot-derived dopamine agonists may not be limited to heart valves. For nonergot-derived dopamine agonists, no drug safety signals were evident.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B02B06`
C03	`01`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 01`
C03	`01`	`X`	`ENG`	`@0 Nervous system diseases @5 01`
C03	`01`	`X`	`SPA`	`@0 Sistema nervioso patología @5 01`
C03	`02`	`X`	`FRE`	`@0 Stimulant dopaminergique @5 09`
C03	`02`	`X`	`ENG`	`@0 Dopamine agonist @5 09`
C03	`02`	`X`	`SPA`	`@0 Estimulante dopaminérgico @5 09`
C03	`03`	`X`	`FRE`	`@0 Fibrose @5 10`
C03	`03`	`X`	`ENG`	`@0 Fibrosis @5 10`
C03	`03`	`X`	`SPA`	`@0 Fibrosis @5 10`
N21				`@1 068`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 09-0094116 INIST
ET :	Cardiac and Noncardiac Fibrotic Reactions Caused by Ergot-and Nonergot-Derived Dopamine Agonists
AU :	ANDERSOHN (Frank); GARBE (Edeltraut)
AF :	Bremen Institute for Prevention Research and Social Medicine, University of Bremen/Allemagne (1 aut., 2 aut.); Institute of Clinical Pharmacology and Toxicology, Charité Universitaetsmedizin Berlin/Allemagne (2 aut.)
DT :	Publication en série; Courte communication, note brève; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2009; Vol. 24; No. 1; Pp. 129-133; Bibl. 19 ref.
LA :	Anglais
EA :	There is growing evidence that the ergot-derived dopamine agonists cabergoline and pergolide can cause fibrotic cardiac valvulopathy. Data on other fibrotic reactions and nonergot-derived dopamine agonists are sparse. Aim of this study was to investigate whether there are signals that dopamine agonists are related to cardiac and other fibrotic reactions. We identified all reports of fibrotic reactions at the heart, lung, and retroperitoneal space associated with dopamine agonists within the US Adverse Event Reporting System database. Disproportionality analyses were used to calculate adjusted reporting odds ratios (RORs). For ergot-derived dopamine agonists (bromocriptine, cabergoline, pergolide), the RORs of all reactions under study were increased, whereas no such increases were observed for nonergot-derived drugs (apomorphine, pramipexole, ropinirole, rotigotine). Fibrotic reactions due to ergot-derived dopamine agonists may not be limited to heart valves. For nonergot-derived dopamine agonists, no drug safety signals were evident.
CC :	002B17; 002B02B06
FD :	Pathologie du système nerveux; Stimulant dopaminergique; Fibrose
ED :	Nervous system diseases; Dopamine agonist; Fibrosis
SD :	Sistema nervioso patología; Estimulante dopaminérgico; Fibrosis
LO :	INIST-20953.354000186473060210
ID :	09-0094116

Links to Exploration step

Pascal:09-0094116

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Cardiac and Noncardiac Fibrotic Reactions Caused by Ergot-and Nonergot-Derived Dopamine Agonists</title>
<author><name sortKey="Andersohn, Frank" sort="Andersohn, Frank" uniqKey="Andersohn F" first="Frank" last="Andersohn">Frank Andersohn</name>
<affiliation><inist:fA14 i1="01"><s1>Bremen Institute for Prevention Research and Social Medicine, University of Bremen</s1>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Garbe, Edeltraut" sort="Garbe, Edeltraut" uniqKey="Garbe E" first="Edeltraut" last="Garbe">Edeltraut Garbe</name>
<affiliation><inist:fA14 i1="01"><s1>Bremen Institute for Prevention Research and Social Medicine, University of Bremen</s1>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Institute of Clinical Pharmacology and Toxicology, Charité Universitaetsmedizin Berlin</s1>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">09-0094116</idno>
<date when="2009">2009</date>
<idno type="stanalyst">PASCAL 09-0094116 INIST</idno>
<idno type="RBID">Pascal:09-0094116</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000F97</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Cardiac and Noncardiac Fibrotic Reactions Caused by Ergot-and Nonergot-Derived Dopamine Agonists</title>
<author><name sortKey="Andersohn, Frank" sort="Andersohn, Frank" uniqKey="Andersohn F" first="Frank" last="Andersohn">Frank Andersohn</name>
<affiliation><inist:fA14 i1="01"><s1>Bremen Institute for Prevention Research and Social Medicine, University of Bremen</s1>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Garbe, Edeltraut" sort="Garbe, Edeltraut" uniqKey="Garbe E" first="Edeltraut" last="Garbe">Edeltraut Garbe</name>
<affiliation><inist:fA14 i1="01"><s1>Bremen Institute for Prevention Research and Social Medicine, University of Bremen</s1>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Institute of Clinical Pharmacology and Toxicology, Charité Universitaetsmedizin Berlin</s1>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2009">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Dopamine agonist</term>
<term>Fibrosis</term>
<term>Nervous system diseases</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Pathologie du   système nerveux</term>
<term>Stimulant dopaminergique</term>
<term>Fibrose</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">There is growing evidence that the ergot-derived dopamine agonists cabergoline and pergolide can cause fibrotic cardiac valvulopathy. Data on other fibrotic reactions and nonergot-derived dopamine agonists are sparse. Aim of this study was to investigate whether there are signals that dopamine agonists are related to cardiac and other fibrotic reactions. We identified all reports of fibrotic reactions at the heart, lung, and retroperitoneal space associated with dopamine agonists within the US Adverse Event Reporting System database. Disproportionality analyses were used to calculate adjusted reporting odds ratios (RORs). For ergot-derived dopamine agonists (bromocriptine, cabergoline, pergolide), the RORs of all reactions under study were increased, whereas no such increases were observed for nonergot-derived drugs (apomorphine, pramipexole, ropinirole, rotigotine). Fibrotic reactions due to ergot-derived dopamine agonists may not be limited to heart valves. For nonergot-derived dopamine agonists, no drug safety signals were evident.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>24</s2>
</fA05>
<fA06><s2>1</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Cardiac and Noncardiac Fibrotic Reactions Caused by Ergot-and Nonergot-Derived Dopamine Agonists</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>ANDERSOHN (Frank)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>GARBE (Edeltraut)</s1>
</fA11>
<fA14 i1="01"><s1>Bremen Institute for Prevention Research and Social Medicine, University of Bremen</s1>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Institute of Clinical Pharmacology and Toxicology, Charité Universitaetsmedizin Berlin</s1>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA20><s1>129-133</s1>
</fA20>
<fA21><s1>2009</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000186473060210</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2009 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>19 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>09-0094116</s0>
</fA47>
<fA60><s1>P</s1>
<s3>CC</s3>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>There is growing evidence that the ergot-derived dopamine agonists cabergoline and pergolide can cause fibrotic cardiac valvulopathy. Data on other fibrotic reactions and nonergot-derived dopamine agonists are sparse. Aim of this study was to investigate whether there are signals that dopamine agonists are related to cardiac and other fibrotic reactions. We identified all reports of fibrotic reactions at the heart, lung, and retroperitoneal space associated with dopamine agonists within the US Adverse Event Reporting System database. Disproportionality analyses were used to calculate adjusted reporting odds ratios (RORs). For ergot-derived dopamine agonists (bromocriptine, cabergoline, pergolide), the RORs of all reactions under study were increased, whereas no such increases were observed for nonergot-derived drugs (apomorphine, pramipexole, ropinirole, rotigotine). Fibrotic reactions due to ergot-derived dopamine agonists may not be limited to heart valves. For nonergot-derived dopamine agonists, no drug safety signals were evident.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B02B06</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Stimulant dopaminergique</s0>
<s5>09</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Dopamine agonist</s0>
<s5>09</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Estimulante dopaminérgico</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Fibrose</s0>
<s5>10</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Fibrosis</s0>
<s5>10</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Fibrosis</s0>
<s5>10</s5>
</fC03>
<fN21><s1>068</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 09-0094116 INIST</NO>
<ET>Cardiac and Noncardiac Fibrotic Reactions Caused by Ergot-and Nonergot-Derived Dopamine Agonists</ET>
<AU>ANDERSOHN (Frank); GARBE (Edeltraut)</AU>
<AF>Bremen Institute for Prevention Research and Social Medicine, University of Bremen/Allemagne (1 aut., 2 aut.); Institute of Clinical Pharmacology and Toxicology, Charité Universitaetsmedizin Berlin/Allemagne (2 aut.)</AF>
<DT>Publication en série; Courte communication, note brève; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2009; Vol. 24; No. 1; Pp. 129-133; Bibl. 19 ref.</SO>
<LA>Anglais</LA>
<EA>There is growing evidence that the ergot-derived dopamine agonists cabergoline and pergolide can cause fibrotic cardiac valvulopathy. Data on other fibrotic reactions and nonergot-derived dopamine agonists are sparse. Aim of this study was to investigate whether there are signals that dopamine agonists are related to cardiac and other fibrotic reactions. We identified all reports of fibrotic reactions at the heart, lung, and retroperitoneal space associated with dopamine agonists within the US Adverse Event Reporting System database. Disproportionality analyses were used to calculate adjusted reporting odds ratios (RORs). For ergot-derived dopamine agonists (bromocriptine, cabergoline, pergolide), the RORs of all reactions under study were increased, whereas no such increases were observed for nonergot-derived drugs (apomorphine, pramipexole, ropinirole, rotigotine). Fibrotic reactions due to ergot-derived dopamine agonists may not be limited to heart valves. For nonergot-derived dopamine agonists, no drug safety signals were evident.</EA>
<CC>002B17; 002B02B06</CC>
<FD>Pathologie du   système nerveux; Stimulant dopaminergique; Fibrose</FD>
<ED>Nervous system diseases; Dopamine agonist; Fibrosis</ED>
<SD>Sistema nervioso patología; Estimulante dopaminérgico; Fibrosis</SD>
<LO>INIST-20953.354000186473060210</LO>
<ID>09-0094116</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F97 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000F97 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:09-0094116
   |texte=   Cardiac and Noncardiac Fibrotic Reactions Caused by Ergot-and Nonergot-Derived Dopamine Agonists
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Cardiac and Noncardiac Fibrotic Reactions Caused by Ergot-and Nonergot-Derived Dopamine Agonists

Cardiac and Noncardiac Fibrotic Reactions Caused by Ergot-and Nonergot-Derived Dopamine Agonists

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri